Roche's $510M-Upfront Hansoh ADC Deal, Proofpoint's $6.3B Varonis Buy, and Four More Deals
Six transactions from October 15–21, 2026, led by Roche's licence for Hansoh's antibody-drug conjugate platform at up to $15 billion in milestones — a week in which three separate buyers each paid about $6 billion in cash for a software company.
Six transactions with enough public detail to compare were announced between October 15 and October 21, 2026.
Three of them were software companies bought for about $6 billion each, all in cash. Two were biotech. One is small enough that its price is a report rather than a disclosure.
The table runs from the largest headline value to the smallest. Headline value is not the same as cash committed, and the first row is where the two diverge most.
Deal snapshot
| Sector | Buyer / target | Date | Structure and status | Disclosed value | What the buyer is buying |
|---|---|---|---|---|---|
| Biotech | Roche / Hansoh Pharmaceutical ADC portfolio | Oct. 19 | Collaboration and licence; Hansoh runs each programme through a global Phase 1a, Roche develops and sells outside Greater China; no closing date announced | Up to more than $15 billion: $400 million upfront, $110 million on the first anniversary, the remainder in milestones, plus tiered royalties 1 | An antibody-drug conjugate platform and a portfolio built on it: two of Hansoh's own preclinical candidates and further programmes aimed at targets Roche nominates 1 |
| Software | Proofpoint (Thoma Bravo) / Varonis Systems | Oct. 15 | Definitive agreement, all cash; approved unanimously by the Varonis board; closing expected in the first half of 2027 | About $6.3 billion, at $49.75 a share 2 | Software that finds an organisation's sensitive data, maps which people and programs can reach it, and watches for misuse, sold on the argument that AI agents make that map urgent 2 |
| Software | GTCR and Elliott / CCC Intelligent Solutions | Oct. 15 | Definitive agreement, all cash; not subject to a financing condition; closing expected in the first quarter of 2027 | About $6.1 billion of enterprise value, at $7.75 a share 3 | The software network on which American insurers, repair shops, automakers and parts suppliers settle claims, built on 40 years of claims data 3 |
| Software | Salesforce / Braze | Oct. 20 | Definitive agreement, all cash; closing expected in Salesforce's fiscal 2028 | About $5.66 billion of enterprise value, at $47.50 a share 4 | A customer engagement platform that reads live behaviour and decides which message, on which channel, reaches a consumer next 4 |
| Biotech | Merck KGaA / Silence Therapeutics | Oct. 19 | Definitive agreement by UK scheme of arrangement, all cash; closing expected in the first quarter of 2027 | About $1.3 billion, at $20 per American depositary share 5 | An siRNA platform and two clinical programmes, one of them about to start late-stage testing in a rare blood cancer 5 |
| Fintech | Intuit / Sequence | Oct. 15 | Definitive agreement; terms not disclosed by the parties | Not disclosed; reported at about $200 million by a source close to the deal 67 | Software that prices, bills, invoices, collects and recognises revenue for companies selling on usage rather than on seats 6 |
Deal notes
Roche licenses Hansoh's ADC platform for $510 million down and up to $15 billion more
Hansoh Pharmaceutical said on October 19 that it had licensed a portfolio of antibody-drug conjugates to Roche. 1
An antibody-drug conjugate joins an antibody that finds a tumour cell to a payload that kills it. The engineering lies in the linker that holds the two together until the right moment. 1
Roche pays $400 million up front and $110 million on the first anniversary. A further $15 billion or more is tied to development, approval and sales milestones, with tiered royalties on top. 1
The portfolio is not one drug. Two of the programmes are Hansoh's own preclinical candidates. The rest are built against targets Roche nominates, using Hansoh's conjugation technology. 1
Hansoh runs each programme through a global Phase 1a, then hands it over. Roche develops and sells worldwide except in mainland China, Hong Kong, Macau and Taiwan, which Hansoh keeps. 1
Hansoh can also pick up to two programmes, fund part of their development outside Greater China, and take extra US commercial upside in return. 1
This is the second ADC agreement between the two companies, after one announced last year. 1
Proofpoint pays $6.3 billion in cash for Varonis, with its owner's committed equity behind it
Varonis agreed on October 15 to be bought by Proofpoint, a Thoma Bravo portfolio company, for $49.75 a share in cash. The transaction is valued at about $6.3 billion. 2
Varonis finds an organisation's sensitive files wherever they sit, maps who and what can reach them, and monitors misuse around the clock. Both companies now sell that map as the precondition for letting AI agents touch company systems. 2
The release quotes two premiums against two dates. The $49.75 is 52% above the $32.71 close on June 22, the last full trading day before the first reports of a possible sale. 2
It is 17% above the $42.35 close on September 1, the last trading day before a second round of reports. The shares had risen 29% in between, on speculation alone. 2
Proofpoint put the price at 8.4 times Varonis's trailing twelve-month revenue and 53 times its trailing free cash flow, both measured to June 30. 2
The financing is disclosed, which is unusual. Thoma Bravo is providing committed equity and has secured debt commitments. Ontario Teachers' Pension Plan is also investing into Proofpoint alongside the transaction. 2
The two businesses sell to the same buyer. The combined company would serve more than 16,000 enterprises, and Proofpoint alone counts more than 80 of the Fortune 100. 2
Varonis's chief executive, Yaki Faitelson, said the sale followed an evaluation by a committee of independent directors that included outreach to strategic and financial buyers. 2
Closing is expected in the first half of 2027. 2
GTCR and Elliott take CCC private at $6.1 billion
CCC Intelligent Solutions agreed on October 15 to an all-cash sale at $7.75 a share to a consortium led by GTCR and including Elliott Investment Management. Enterprise value is about $6.1 billion. 3
CCC runs the software layer of the American car claims and repair economy. It connects more than 35,000 insurers, repairers, automakers and parts suppliers, and has spent over a decade putting AI into those workflows. 3
The $7.75 is 44% above CCC's close on July 9, which the company identifies as the last trading day before media speculation about a sale. Against the 30-day average to that date, the premium is 59%. 3
CCC reported $285.9 million of revenue in the second quarter, up 9.8%, and guided to $1.158 billion to $1.164 billion for the full year. 8 Against the top of that range, $6.1 billion is about 5.3 times revenue.
The transaction carries no financing condition. J.P. Morgan is lead financial adviser to GTCR and lead arranger of committed financing, and Citi is also advising and participating in that financing. 3
Elliott's head of global private equity, David Kerko, called CCC the trusted third party at the centre of the industry, with data advantages and network benefits. He described it as a durable franchise in vertical software, which AI "will only make more valuable". 3
Chief executive Githesh Ramamurthy said the announcement followed a thorough review of strategic options. Closing is expected in the first quarter of 2027. 3
Salesforce pays $5.66 billion in cash for Braze
Salesforce said on October 20 that it had agreed to buy Braze for $47.50 a share in cash, an enterprise value of about $5.66 billion. 4
Braze decides what a consumer sees next. It streams live behaviour from apps and websites, keeps each profile current, and fires messages across mobile, email, SMS, WhatsApp and in-app surfaces. 4
Braze reported $738.2 million of revenue in the fiscal year to January 31, 2026, up 24.4%, and served about 2,770 customers at the announcement. 9 Against $5.66 billion, that is about 7.7 times the last full fiscal year.
Braze closed at $30.04 on Monday, so $47.50 is a 58% premium. The shares closed at $45.57 on Tuesday, up 51% and still short of the offer. 10
Salesforce expects no change to its fiscal 2027 guidance and to close in its fiscal 2028. 4
This is Salesforce's second large purchase this year. It agreed in June to buy the AI customer service company Fin for about $3.6 billion. 10
Braze would sit inside Marketing Cloud, where Salesforce now argues that real-time behaviour, not a stored profile, has to drive personalisation. 4
Merck KGaA pays $1.3 billion for Silence Therapeutics
Merck KGaA said on October 19 that it would buy Silence Therapeutics for $20 an American depositary share in cash, about $1.3 billion, a 130% premium to the previous close. 5 Silence's US shares more than doubled in morning trading.
Silence makes siRNA medicines: short RNA strands that switch off the gene messages which would otherwise produce a disease-causing protein. 5
The lead candidate, divesiran, is expected to enter late-stage testing in phlebotomy-dependent polycythemia vera, a rare blood cancer in which the marrow makes too many red cells. Patients manage it with regular blood draws. 5
If approved, divesiran would compete with Mimrylo, the Takeda and Protagonist Therapeutics drug. Takeda has indicated $1 billion to $2 billion of peak sales for Mimrylo in that disease. 5
William Blair's Myles Minter said the valuation "does appear inexpensive" even before counting the broader mRNAi GOLD siRNA platform that comes with the company. 5
Silence also has zerlasiran in development for high lipoprotein(a), a protein linked to heart disease, plus earlier programmes in cholesterol, obesity and immune disease. 5
For Merck this is the third major acquisition in under two years, after SpringWorks Therapeutics at $3.9 billion in 2025 and a pending $11.3 billion takeover of the tools maker Bio-Techne. 5
The purchase runs through a UK scheme of arrangement and is expected to close in the first quarter of 2027. 5
Intuit buys a billing platform and does not say what it paid
Intuit said on October 15 that it had agreed to buy Sequence, a revenue management company based in London and New York. Intuit did not disclose the terms. 6
Sequence automates what happens between a signed contract and booked revenue: configuring the deal, setting the price, invoicing, chasing payment and recognising the revenue. 6
The company was founded in 2021 and raised $19 million in 2022. Its co-founders are Riya Grover and Eamon Jubbawy; Jubbawy earlier co-founded the identity verification business Onfido. 7
A source close to the deal put the price at around $200 million. That is a report, not a disclosed figure. 7
Intuit's stated reason is the mid-market. Pricing and billing on usage is one of the reasons a growing company changes its accounting system, and Sequence takes Intuit Enterprise Suite into software and professional services. 6
Themes across the week
Three software companies cleared at about $6 billion and five to eight times revenue
The three software transactions of the week were the same size to within about 10%. Varonis went for $6.3 billion, CCC for $6.1 billion of enterprise value, Braze for $5.66 billion. All three were paid in cash.
The multiples were also close, once calculated against what each target disclosed. Varonis's own release puts it at 8.4 times trailing revenue. 2 CCC's $6.1 billion is about 5.3 times the top of its own full-year guidance. 8 Braze's $5.66 billion is about 7.7 times its revenue for the year to January 31, 2026. 9
Only the Varonis multiple is the seller's own number. The other two are this briefing's arithmetic, and the fiscal periods do not line up: June 30 for Varonis, calendar 2026 guidance for CCC, January 31, 2026 for Braze. Read as a band, the week cleared at roughly five to eight times revenue.
The three targets have almost nothing in common commercially. One secures data, one settles car repairs, one chooses marketing messages. What they share is a record that gets more valuable the more often something reads it: permission maps, claims outcomes, engagement events.
The buyers were less alike than the targets. Proofpoint is a sponsor-owned platform buying a listed competitor, GTCR and Elliott are a consortium of private investment firms buying a listed company, and Salesforce is a strategic writing a cheque from its own balance sheet. Cash, in all three cases.
Two of the three premiums are measured from a share price that already knew
A premium is a fact about a date. Choose an earlier date and the number gets bigger.
Varonis's announcement quotes both dates. The $49.75 offer is 52% above the June 22 close, before the first report of a sale, and 17% above the September 1 close, before a second round of reports. 2 Between those two dates the stock rose 29% with no transaction attached.
CCC's announcement quotes one date, July 9, the last trading day before speculation, and 44% is measured from it. 3 The same release puts the premium at 59% against the 30-day average, which is higher because the shares had fallen over that month.
Neither board was passive about that gap. Varonis's independent committee ran outreach to strategic and financial buyers. 2 CCC's chief executive described a thorough review of strategic options. 3
Braze is the counter-example and shows the same mechanics from the other side. Salesforce's 58% is measured from a close that had not moved on takeover reports, and Braze still closed 4% below the offer on the announcement day. 10
For anyone comparing premiums across a week, the measurement date matters as much as the percentage. A premium quoted against a pre-speculation close prices in the option value the market had already assigned to a sale.
Both biotech buyers paid for a platform, and only one bought the company
Merck wrote a single cheque for $1.3 billion and took Silence whole: the siRNA chemistry, the manufacturing, the two clinical programmes and the platform underneath them. 5
Roche committed $510 million and took a share of a portfolio, programme by programme, with the rest payable only if the programmes reach the market. 1
The difference tracks where the science sits. Silence's divesiran has been through mid-stage testing and is expected to move into late-stage work; a buyer can underwrite that readout. 5 Hansoh's own two candidates are preclinical, and the remaining programmes do not exist until Roche names a target. 1
What both buyers actually bought is the capacity to make more of the same thing. Merck's analyst case rests on the mRNAi GOLD platform sitting alongside divesiran. 5 Roche gets a partner that will build conjugates against targets Roche chooses.
Roche has now run that arrangement with the same counterparty twice. This is its second ADC agreement with Hansoh, after one signed last year. 1 A second order for the same production line is a statement about throughput rather than about any one molecule.
Coverage note
Deals disclosed in the October 15–21 window that this briefing considered and left out of the table.
- Penske Corp. and Mitsui & Co., the two largest shareholders of Penske Automotive Group, agreed on October 15 to take the dealership group private at $212 a share in cash, an enterprise value of about $16.3 billion. It is a car retailer, outside the three sectors this briefing covers. 11
- SoftBank Group is weighing an acquisition of the security services company Allied Universal at about $18 billion, Reuters reported on October 16. Deliberations are preliminary, no price has been decided and no agreement exists. 12
- Fairfax Financial's purchase of 60.7% of IDBI Bank for 528.78 billion rupees, about $5.56 billion, was approved by the Indian government on October 14, before this window opened. 13
- Ambrose Healthcare bought AM-Pharma for up to €161 million, an undisclosed upfront payment plus milestones and royalties, for an enzyme replacement therapy in hypophosphatasia. 14
- Cohere signed a letter of intent to buy Aisle, a cybersecurity startup that uses AI to find software vulnerabilities. Terms were not disclosed. 15
Two rules decided the rest. A transaction announced before October 15 stays out even if it completed inside the week. A transaction with no disclosed price and no reported estimate stays out as well.
References
- 1
- 2
- 3
- 4Salesforce Signs Definitive Agreement to Acquire Braze
investor.salesforce.com
- 5
- 6Intuit to Acquire AI-Native Revenue Management Platform Sequence
investors.intuit.com
- 7Intuit Sequence deal values UK AI fintech at reported $200m
bmmagazine.co.uk
- 8
- 9Braze Reports Fiscal Year and Fourth Quarter 2026 Results
investors.braze.com
- 10
- 11
- 12
- 13
- 14Ambrose expands rare disease pipeline with €161M AM-Pharma acquisition
european-biotechnology.com
- 15
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.